Brief: China Biotech Services Expects Net Profit Attributable Of Not Less Than Hk$34 Mln For Q1
05/05/2022 11:36
May 5 (Reuters) - China Biotech Services Holdings Ltd
8037.HK :
* EXPECTS NET PROFIT ATTRIBUTABLE OF NOT LESS THAN HK$34
MILLION
FOR 2022 Q1
* EXPECTED RESULT DUE TO DEMANDS FOR RAPID ANTIGEN TEST
KITS,
COVID-19 TESTING SERVICES DURING PERIOD
Source text for Eikon: ID:nHKS6RnpwY
Further company coverage: 8037.HK
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)